 |
 |
Bayer 'pulls out of Titan drug project' 02 Jul 2008 Bayer is to end its cooperation with Titan Pharmaceuticals over the Parkinson's treatment Spheramine, Thomson Financial News has reported. Initial results revealed today by Titan show the drug show did not meet primary or key secondary endpoints in a phase-two study. The news provider states Bayer spokesperson Jost Reinhard confirmed the company will no longer be developing or investing in the drug. Announcing the initial results for Spheramine, president and chief executive officer of Titan Dr Marc Rubin said: "We are disappointed by these data as we have been diligently working to address the critical unmet medical need facing Parkinson's patients." He added his company will continue to analyse the data to help determine the next steps it will take. In May, Titan reported net losses of $5.7 million (£2.9 million) for the first quarter of the year, compared with a net loss of $3.6 million for the same period in 2007. The company said expenditure on research and development (R&D) was approximately $3.8 million in the first quarter, which was almost $2 million higher than R&D spending during the first three months of last year. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn